About AAV Vector Development & Manufacturing: Process Development, Analytics & GMP | Advanced Therapies Workshops | #EGeneCell 2026

Join AAV process development scientists, manufacturing directors, analytical experts, CDMO strategists, and technical operations leaders for an intensive workshop dedicated to the most pressing challenges in AAV gene therapy manufacturing.

AAV remains the dominant platform for in vivo gene therapy, and the challenges of manufacturing it at scale, with consistent quality and at commercially viable cost, remain among the most pressing in the entire field. Yield, purity, empty/full capsid ratio, CDMO capacity constraints, and cost of goods continue to limit the speed and accessibility of AAV-based therapies.

From the earliest vector design decisions — including the emerging role of CpG content in immunogenicity and durability — through to commercial-scale GMP manufacturing strategy, CDMO partnerships, and cost-of-goods modelling, this workshop covers the full AAV manufacturing value chain.

Why Attend?

• Vector Design for Durability & Safety — understand how sequence-level decisions including CpG content affect expression durability, immunogenicity risk, and platform performance
• Scalable AAV Manufacturing Systems — compare Sf-9/baculovirus and HEK293 platforms on yield, purity, GMP compliance, and regulatory acceptability
• CDMO Partnership & Technology Transfer — identify and mitigate the most common risks in CDMO relationships: capacity lock-in, IP protection, tech transfer gaps, and quality oversight
• Cost of Goods Reduction — model AAV CoGs, identify the highest-impact levers for reduction, and evaluate trade-offs between platform choice, in-house vs. outsourced manufacturing, and process intensification
• Viral Vector Characterisation & Release Testing — build a comprehensive analytical and release testing strategy for AAV products that satisfies EMA and FDA expectations

Industry Trends, Pain Points & Critical Issues

• AAV Manufacturing Scalability Remains the Field's Biggest Bottleneck — yield, purity, and process consistency challenges continue to limit the speed and cost of AAV clinical and commercial supply
• Cost of Goods Threatening Commercial Viability — high AAV manufacturing CoGs continue to threaten the commercial sustainability of gene therapy, and effective cost-reduction strategies remain poorly understood
• CDMO Capacity Constraints & Partnership Risks — limited CDMO capacity creates strategic vulnerability for sponsors, and technology transfer failures remain frequent
• Immunogenicity & Durability Concerns Growing — emerging evidence on vector genome composition, including CpG content, is creating new sequence-level design and risk management obligations
• Empty Capsid Ratio & Purity Challenges — controlling the empty/full capsid ratio and achieving consistently high purity remain difficult process challenges with direct regulatory and clinical implications
• Regulatory Expectations for AAV Analytics Tightening — EMA and FDA are raising expectations for AAV characterisation, titer determination, and impurity profiling, increasing analytical complexity and release timelines

What to Expect

• Expert-Led Workshop-Style Presentations — process development scientists, manufacturing directors, and AAV platform experts walk through real manufacturing challenges using structured case studies and worked process scenarios
• Interactive Panel Discussion — From Lab to Launch: What Does It Really Take to Scale AAV Manufacturing?
• Live Expert Q&A & Downloadable Resources — take home post-webinar materials 

Join Us

The AAV Vector Development & Manufacturing | Advanced Therapies Workshops 2026 is the premier platform for AAV manufacturing excellence. If you are working to develop, scale, or commercialise AAV gene therapy manufacturing, this workshop will deliver the technical knowledge, strategic frameworks, and industry partnerships essential for success. Secure your place at #EGeneCell 2026 and be part of the community solving the hardest problems in gene therapy manufacturing.